← back to search

François Durand

Alibaba Group (United States) · FR
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Organ Transplantation Techniques and Outcomes, and Drug-Induced Hepatotoxicity and Protection.
h-index
90
citations
35,149
works
748
NIH funding
primary concept
Medicine
email

Recent publications

Occult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: insights into the role of metagenomics
American Journal of Transplantation 2026cited by 3position: contributordoi
Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.
2026cited by 0position: contributordoi
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia
Hepatology International 2025cited by 46position: middledoi
Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A French National Cohort Study Including 571 Patients
The American Journal of Gastroenterology 2025cited by 8position: middledoi
Reply to: “Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin”
Journal of Hepatology 2025cited by 4position: contributordoi
Reply to: “Inclusion of patients with active urinary sediment in treatment of hepatorenal syndrome”
Journal of Hepatology 2025cited by 0position: contributordoi
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
Journal of Hepatology 2024cited by 169position: lastdoi
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.
2024cited by 114position: contributordoi
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies
˜The œLancet. Gastroenterology & hepatology 2024cited by 64position: middledoi
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis
Gut 2024cited by 21position: middledoi
Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
2024cited by 11position: contributordoi
Identification of liver transplant biopsy phenotypes associated with distinct liver biological markers and allograft survival.
2024cited by 4position: contributordoi
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosis.
2024cited by 3position: contributordoi
Fluid resuscitation in patients with cirrhosis and sepsis: A multidisciplinary perspective
Journal of Hepatology 2023cited by 42position: contributordoi
Preventing Small-for-size Syndrome in Living Donor Liver Transplantation: Guidelines From the ILTS-iLDLT-LTSI Consensus Conference
Transplantation 2023cited by 25position: middledoi
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis
Gut 2023cited by 25position: middledoi
Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors
Hepatology 2023cited by 21position: middledoi
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections—Results from the ICA “Global Study” (EABCIR-Global Study)
Hepatology 2023cited by 18position: middledoi
Reply: Aberrant arteries-1 may be better than 2 for the liver, but maybe not the bile duct.
2023cited by 0position: contributordoi
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation
JHEP Reports 2022cited by 35position: middledoi
Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome
Transplantation 2022cited by 34position: middledoi
Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: A prospective analysis of 302 procedures.
2022cited by 21position: contributordoi
Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
2022cited by 8position: contributordoi
The Use of Rifaximin in Patients With Cirrhosis
Hepatology 2021cited by 139position: middledoi
Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF
Frontiers in Immunology 2021cited by 87position: middledoi
Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score
Journal of Hepatology 2021cited by 62position: middledoi
Covid-19 in liver transplant recipients: the French SOT COVID registry
Clinics and Research in Hepatology and Gastroenterology 2021cited by 49position: middledoi
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Hepatology Communications 2021cited by 22position: middledoi
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
JHEP Reports 2021cited by 21position: middledoi
Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients
Clinics and Research in Hepatology and Gastroenterology 2021cited by 19position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2026)Vicente Arroyo · European Foundation for the Study of Chronic Liver Failure7 papers (2013–2021)Pere Ginès · Centre for Biomedical Network Research on Rare Diseases7 papers (2013–2024)Richard Moreau · KU Leuven5 papers (2013–2021)Paolo Angeli · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo5 papers (2013–2021)Mauro Bernardi · University of Bologna4 papers (2013–2015)Jérôme Dumortier · Hospices Civils de Lyon4 papers (2016–2026)Rajiv Jalan · Roland Hill (United Kingdom)4 papers (2013–2015)Paolo Caraceni · Istituto delle Scienze Neurologiche di Bologna4 papers (2014–2021)Jonel Trebicka · Nordic Bioscience (Denmark)3 papers (2013–2021)Nassim Kamar · French Clinical Research Infrastructure Network3 papers (2017–2026)Wim Laleman · Vrije Universiteit Amsterdam3 papers (2013–2019)Vı́ctor Vargas · University of Chile3 papers (2019–2024)Carlo Alessandria · Azienda Ospedaliero Universitaria San Giovanni Battista3 papers (2013–2021) · 3 papers (2013–2016)Alexander L. Gerbes · LMU Klinikum3 papers (2014–2015)Shiv Kumar Sarin · Berlin University of the Arts2 papers (2015–2015)Mitra K. Nadim · University of Southern California2 papers (2024–2025) · 2 papers (2014–2016)Samuel S. Lee · University of Calgary2 papers (2015–2015)